AstraZeneca plc’s Hold Rating Reaffirmed at Panmure Gordon (AZN)
Other equities research analysts have also recently issued reports about the stock. Analysts at Deutsche Bank reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Friday, August 22nd. Separately, analysts at Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a research note on Friday, August 22nd. Finally, analysts at Credit Suisse reiterated a “neutral” rating on shares of AstraZeneca plc in a research note on Thursday, August 14th. Four research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have issued a buy rating to the company’s stock. AstraZeneca plc currently has a consensus rating of “Hold” and a consensus target price of $57.00.
Shares of AstraZeneca plc (NYSE:AZN) traded up 1.17% on Wednesday, hitting $75.51. 1,206,301 shares of the company’s stock traded hands. AstraZeneca plc has a 52-week low of $48.53 and a 52-week high of $82.68. The stock has a 50-day moving average of $72.64 and a 200-day moving average of $71.21. The company has a market cap of $95.369 billion and a P/E ratio of 46.56.
AstraZeneca plc (NYSE:AZN) last released its earnings data on Thursday, July 31st. The company reported $1.30 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.09 by $0.21. The company had revenue of $6.45 billion for the quarter, compared to the consensus estimate of $6.24 billion. During the same quarter last year, the company posted $1.20 earnings per share. AstraZeneca plc’s revenue was up 3.6% compared to the same quarter last year. Analysts expect that AstraZeneca plc will post $4.39 EPS for the current fiscal year.
The company also recently declared a semiannual dividend, which is scheduled for Monday, September 15th. Stockholders of record on Friday, August 15th will be given a dividend of $0.90 per share. This represents a yield of 2.48%. The ex-dividend date of this dividend is Wednesday, August 13th.
AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.